Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.1.1 (
hexokinase
)
5,274
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Polymyxin B
(
PMB
), a cyclic decapeptide antibiotic, inhibits the hypoglycemic effect of insulin in vivo. To elucidate the mechanism of
PMB
action, we have studied its effect in vitro on insulin-stimulated pathways in the mouse skeletal muscle.
PMB
, added to the incubation mixture, specifically inhibited insulin-stimulated 2-deoxyglucose transport and alpha-aminoisobutyric acid uptake in the isolated soleus muscle but did not affect the basal rates of transport (measured in the absence of insulin).
PMB
did not alter insulin binding and
hexokinase
activity.
PMB
effect was observed at all deoxyglucose concentrations tested, and
PMB
was also able to inhibit vanadate-stimulated glucose transport. By contrast, insulin activation of glycogen synthase was not prevented by
PMB
. Basal and maximally insulin-stimulated insulin receptor tyrosine kinase activity, tested in a cell-free system, was similar for both autophosphorylation and phosphorylation of exogenous substrates in the absence or in the presence of
PMB
. Furthermore, the insulin sensitivity of the kinase was increased in the presence of
PMB
. Our results suggest that the anti-insulin effect of
PMB
observed in vivo is due to an inhibition of insulin-stimulated glucose transport in the skeletal muscle perhaps through a specific blockade of the insulin-induced translocation of the glucose carriers.
...
PMID:Polymyxin B selectively inhibits insulin effects on transport in isolated muscle. 303 Jan 25
